103 related articles for article (PubMed ID: 22127421)
1. Development of a novel fluorescence polarization-based assay for studying the β-catenin/Tcf4 interaction.
Tian W; Xu Y; Han X; Duggineni S; Han X; Huang Z; An J
J Biomol Screen; 2012 Apr; 17(4):530-4. PubMed ID: 22127421
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.
Tian W; Han X; Yan M; Xu Y; Duggineni S; Lin N; Luo G; Li YM; Han X; Huang Z; An J
Biochemistry; 2012 Jan; 51(2):724-31. PubMed ID: 22224445
[TBL] [Abstract][Full Text] [Related]
3. New homogeneous high-throughput assays for inhibitors of β-catenin/Tcf protein-protein interactions.
Zhang M; Huang Z; Yu B; Ji H
Anal Biochem; 2012 May; 424(1):57-63. PubMed ID: 22370279
[TBL] [Abstract][Full Text] [Related]
4. Phospholipase D1 drives a positive feedback loop to reinforce the Wnt/beta-catenin/TCF signaling axis.
Kang DW; Lee SH; Yoon JW; Park WS; Choi KY; Min do S
Cancer Res; 2010 May; 70(10):4233-42. PubMed ID: 20442281
[TBL] [Abstract][Full Text] [Related]
5. Optimizations of a novel fluorescence polarization-based high-throughput screening assay for β-catenin/LEF1 interaction inhibitors.
Chen Y; Fu Z; Li D; Yue Y; Liu X
Anal Biochem; 2021 Jan; 612():113966. PubMed ID: 32956692
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Tcf4 G13ANDE17 binding site to selectively disrupt β-catenin/T-cell factor protein-protein interactions.
Huang Z; Zhang M; Burton SD; Katsakhyan LN; Ji H
ACS Chem Biol; 2014 Jan; 9(1):193-201. PubMed ID: 24191653
[TBL] [Abstract][Full Text] [Related]
8. β-catenin/Tcf-4 complex transcriptionally regulates AKT1 in glioma.
Chen L; Huang K; Han L; Shi Z; Zhang K; Pu P; Jiang C; Kang C
Int J Oncol; 2011 Oct; 39(4):883-90. PubMed ID: 21720709
[TBL] [Abstract][Full Text] [Related]
9. Identification of Tcf4 residues involved in high-affinity beta-catenin binding.
Omer CA; Miller PJ; Diehl RE; Kral AM
Biochem Biophys Res Commun; 1999 Mar; 256(3):584-90. PubMed ID: 10080941
[TBL] [Abstract][Full Text] [Related]
10. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin.
Choi H; Chun YS; Kim TY; Park JW
Cancer Res; 2010 Dec; 70(24):10101-11. PubMed ID: 21159632
[TBL] [Abstract][Full Text] [Related]
11. KLF4 and SOX9 transcription factors antagonize β-catenin and inhibit TCF-activity in cancer cells.
Sellak H; Wu S; Lincoln TM
Biochim Biophys Acta; 2012 Oct; 1823(10):1666-75. PubMed ID: 22766303
[TBL] [Abstract][Full Text] [Related]
12. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription.
Navarro D; Agra N; Pestaña A; Alonso J; González-Sancho JM
Carcinogenesis; 2010 Mar; 31(3):394-401. PubMed ID: 20019092
[TBL] [Abstract][Full Text] [Related]
13. The Bcl-w promoter is activated by beta-catenin/TCF4 in human colorectal carcinoma cells.
Lapham A; Adams JE; Paterson A; Lee M; Brimmell M; Packham G
Gene; 2009 Mar; 432(1-2):112-7. PubMed ID: 19124064
[TBL] [Abstract][Full Text] [Related]
14. Conserved regulatory motifs in osteogenic gene promoters integrate cooperative effects of canonical Wnt and BMP pathways.
Rodríguez-Carballo E; Ulsamer A; Susperregui AR; Manzanares-Céspedes C; Sánchez-García E; Bartrons R; Rosa JL; Ventura F
J Bone Miner Res; 2011 Apr; 26(4):718-29. PubMed ID: 20878775
[TBL] [Abstract][Full Text] [Related]
15. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
16. Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer.
Takahashi M; Nakamura Y; Obama K; Furukawa Y
Int J Oncol; 2005 Dec; 27(6):1483-7. PubMed ID: 16273202
[TBL] [Abstract][Full Text] [Related]
17. Henryin, an ent-kaurane diterpenoid, inhibits Wnt signaling through interference with β-catenin/TCF4 interaction in colorectal cancer cells.
Li X; Pu J; Jiang S; Su J; Kong L; Mao B; Sun H; Li Y
PLoS One; 2013; 8(7):e68525. PubMed ID: 23844215
[TBL] [Abstract][Full Text] [Related]
18. Tcf4 can specifically recognize beta-catenin using alternative conformations.
Graham TA; Ferkey DM; Mao F; Kimelman D; Xu W
Nat Struct Biol; 2001 Dec; 8(12):1048-52. PubMed ID: 11713475
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors.
Takeda K; Kinoshita I; Shimizu Y; Ohba Y; Itoh T; Matsuno Y; Shichinohe T; Dosaka-Akita H
BMC Cancer; 2008 Nov; 8():328. PubMed ID: 18992165
[TBL] [Abstract][Full Text] [Related]
20. Dishevelled-DEP domain interacting protein (DDIP) inhibits Wnt signaling by promoting TCF4 degradation and disrupting the TCF4/beta-catenin complex.
Zhang H; Zhang H; Zhang Y; Ng SS; Ren F; Wang Y; Duan Y; Chen L; Zhai Y; Guo Q; Chang Z
Cell Signal; 2010 Nov; 22(11):1753-60. PubMed ID: 20603214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
